Point State Capital LP Novo Cure LTD Transaction History

Point State Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$32.0 - $52.4 $23 Million - $37.7 Million	-718,900 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $2.58 Million - $4.17 Million	-130,200 Reduced 15.33%	718,900 $22.5 Million
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $16.4 Million - $20.1 Million	849,100 New	849,100 $18.5 Million
Q4 2017 Feb 14, 2018	SELL	$16.3 - $21.9 $12.3 Million - $16.5 Million	-752,900 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$18.05 - $21.75 $7.6 Million - $9.15 Million	420,900 Added 126.78%	752,900 $14.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	332,000	332,000 $5.74 Million

290

75.6M

1.77M

538K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.